As global markets grapple with concerns over AI-related valuations and economic uncertainties, Asian markets have also faced challenges, particularly in sectors heavily tied to technology. Amidst this backdrop, identifying growth companies with significant insider ownership can be crucial for investors seeking stability and confidence in management's commitment to the company's future.
Top 10 Growth Companies With High Insider Ownership In Asia
| Name | Insider Ownership | Earnings Growth |
| UTI (KOSDAQ:A179900) | 25.2% | 110.4% |
| Suzhou Sunmun Technology (SZSE:300522) | 33.2% | 93.1% |
| Streamax Technology (SZSE:002970) | 32.5% | 33.1% |
| Seers Technology (KOSDAQ:A458870) | 33.9% | 78.8% |
| Novoray (SHSE:688300) | 23.6% | 31.4% |
| Loadstar Capital K.K (TSE:3482) | 31% | 23.6% |
| Laopu Gold (SEHK:6181) | 34.8% | 34.3% |
| J&V Energy Technology (TWSE:6869) | 17.5% | 31.6% |
| Gold Circuit Electronics (TWSE:2368) | 31.4% | 33.6% |
| Fulin Precision (SZSE:300432) | 11.6% | 55.2% |
Let's take a closer look at a couple of our picks from the screened companies.
Horizon Robotics (SEHK:9660)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Horizon Robotics, an investment holding company, provides automotive solutions for passenger vehicles in China and has a market cap of HK$110.77 billion.
Operations: The company's revenue segments include CN¥2.91 billion from automotive solutions and CN¥100.77 million from non-automotive solutions.
Insider Ownership: 15.9%
Horizon Robotics has seen significant insider buying recently, indicating confidence in its growth potential. The company's revenue is forecast to grow at 31.7% annually, outpacing the Hong Kong market's average. Despite a net loss of CNY 5.23 billion for the half year ending June 2025, earnings are expected to grow by 16.1% per year, surpassing market averages. A recent HKD 6.38 billion equity offering suggests strategic capital raising efforts amid ongoing leadership changes and strategic presentations at major conferences.
- Click to explore a detailed breakdown of our findings in Horizon Robotics' earnings growth report.
- According our valuation report, there's an indication that Horizon Robotics' share price might be on the expensive side.
Zhejiang Leapmotor Technology (SEHK:9863)
Simply Wall St Growth Rating: ★★★★★★
Overview: Zhejiang Leapmotor Technology Co., Ltd. focuses on the research and development, production, and sale of new energy vehicles in Mainland China and internationally, with a market cap of HK$75.14 billion.
Operations: The company generates revenue of CN¥47.57 billion from its activities in the production, research and development, and sales of new energy vehicles.
Insider Ownership: 14.9%
Zhejiang Leapmotor Technology demonstrates strong growth potential with forecasted revenue growth of 30.4% annually, surpassing the Hong Kong market average. Insider confidence is evident through substantial recent share purchases and no significant sales, aligning with expectations of profitability within three years. The company trades at a significant discount to its estimated fair value, while analysts anticipate a 53.9% price increase. Recent amendments to the Articles of Association and record vehicle sales further underscore strategic positioning in the market.
- Take a closer look at Zhejiang Leapmotor Technology's potential here in our earnings growth report.
- In light of our recent valuation report, it seems possible that Zhejiang Leapmotor Technology is trading behind its estimated value.
Dalian BIO-CHEM (SHSE:603360)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Dalian BIO-CHEM Company Limited manufactures and distributes bactericides, antiseptics, and fungicides for diverse industrial uses across Europe, the Americas, the Middle East, Africa, and Asia with a market capitalization of CN¥23.61 billion.
Operations: Dalian BIO-CHEM generates revenue through the production and sale of bactericides, antiseptics, and fungicides for various industrial applications across Europe, the Americas, the Middle East, Africa, and Asia.
Insider Ownership: 30.6%
Dalian BIO-CHEM is poised for significant growth, with earnings projected to increase by 28.5% annually, outpacing the Chinese market. Despite a volatile share price and declining profit margins from 27% to 14.7%, insider ownership remains strong with no substantial recent sales. The company's revenue grew to CNY 1.06 billion over nine months, though net income fell due to higher costs, reflecting challenges amid expansion efforts. Recent share buybacks indicate confidence in long-term value creation.
- Unlock comprehensive insights into our analysis of Dalian BIO-CHEM stock in this growth report.
- Upon reviewing our latest valuation report, Dalian BIO-CHEM's share price might be too optimistic.
Summing It All Up
- Take a closer look at our Fast Growing Asian Companies With High Insider Ownership list of 640 companies by clicking here.
- Searching for a Fresh Perspective? These 12 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Valuation is complex, but we're here to simplify it.
Discover if Horizon Robotics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com